A Study of the Effect and Safety of HS-10390 in the Treatment of Participants With Chronic Kidney Disease
A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 182 participants.
Also called NCT07555054
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 182 participants
- Registry
-
NCT07555054
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07555054. Randomized; double masking; primary purpose treatment. Start 2026-05-21 (anticipated); primary completion 2027-11-11 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of the Effect and Safety of HS-10390 in the Treatment of Participants With Chronic Kidney Disease
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- HS-10390
- Intervention (Drug)
- HS-10390
- Intervention (Drug)
- HS-10390
- Intervention (Drug)
- Irbesartan
- Lead sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct07555054- Content hash
2a997b959267fcef006ef4634791bbd14a888a9c6ca3179282e7f9967a658daf